Table 4.
Case reports of infections with daptomycin-non-susceptible enterococci isolates
| Patient |
Indication for DAP use |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| age | sex | Underlying conditions | pathogen | type of infection | DAP treatment | DAP MIC, mg/L | Other antibiotic used/surgery | Final outcome | Reference |
| 53 | M | NR | VAN-resistant E. faecalis | endocarditis (mitral valve) | 6 mg/kg every 24 h for 8 weeks (followed by mitral valve replacement) | >8 (Etest) | prior: NAF, VAN | bacteraemia 10 days after discharge and died soon afterwards | 96 |
| follow-on: LZD | |||||||||
| 55 | F | diabetes mellitus, haemodialysis, AICD | E. faecalis | endocarditis (aortic valve) | 6 mg/kg every 48 h | 32 (microdilution) | follow-on: AMP, GEN, aortic valve replacement, tricuspid valvuloplasty, removal of AICD | cured | 97 |
| 22 | M | Hodgkin's lymphoma, AML, testicular carcinoma | VAN-resistant E. faecium, E. coli | bacteraemia | 6 mg/kg every 24 h for 17 days | >32 (microdilution) | prior: DOX, FEP, VAN, metronidazole | cured | 98 |
| concomitant: MEM | |||||||||
| follow-on: LZD, DOX, catheter removal | |||||||||
| 37 | F | AML | VAN-resistant E. faecium | bacteraemia | 6 mg/kg for 17 days | >32 (microdilution) | prior: TZP, GEN, VAN, AMB, VRC | recurrence of VRE bacteraemia | 99 |
| follow-on: LZD, catheter removal | |||||||||
| 62 | F | myelofibrosis, GVHD | VAN-resistant E. durans | bacteraemia | 6 mg/kg every 48 h for 20 days | 32 (Etest) | prior: FEP, LVX | cured | 95 |
| follow-on: LZD, catheter removal | |||||||||
| NR | M | Crohn's disease | VAN-resistant E. faecium | bacteraemia | NR | 16 (Etest) | prior: Q/D | NR | 94 |
| 64 | F | cryptogenic cirrhosis, haemodialysis | VAN-resistant E. faecalis | bacteraemia | 400 mg every 48 h for ∼14 days | 16 (microdilution) | prior: LZD | died | 100 |
| concomitant: AMK | |||||||||
| follow-on: LZD, AMP | |||||||||
AICD, automated implantable cardioverter-defibrillator; AMB, amphotericin B; AMK, amikacin; AML, acute myeloid leukaemia; AMP, ampicillin; DAP, daptomycin; DOX, doxycycline; F, female; FEP, cefepime; GEN, gentamicin; GVHD, graft-versus-host disease; LVX, levofloxacin; LZD, linezolid; M, male; MEM, meropenem; NAF, nafcillin; NR, not reported; Q/D, quinupristin/dalfopristin; TZP, piperacillin/tazobactam; VAN, vancomycin; VRC, voriconazole; VRE, vancomycin-resistant enterococci.